George Lundberg, MD Editor in Chief at Cancer Commons

  •   George Lundberg, MD

    Research paper from JAMA Network Open curated by Contributing Editor George Lundberg, MD, who notes: 

    This study linked continued opioid use after breast cancer treatment to many serious adverse effects in older women.

    .

  •   George Lundberg, MD

    Research paper from JAMA Oncology curated by Contributing Editor George Lundberg, MD, who notes: 

    This study linked coffee consumption with longer survival and lower death rates in advanced colorectal cancer.

    .

  •   George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The FDA has granted accelerated approval to tafasitamab (brand name Monjuvi) as a second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), based upon overall responses seen in a clinical trial. This is the first FDA approval of a second-line treatment for this condition. There are few, if any, other options.

    .

  •   George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved oral azacitidine (brand name Onureg) based on clinical trial results showing a 10-month improvement in overall survival for patients with acute myeloid leukemia who are ineligible for transplant.

    .

  •   George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    Myelodysplastic syndrome (MDS) commonly occurs before a patient develops acute leukemia, and is largely unresponsive to therapy. Two new clinical trials are entering phase 3 and may offer some hope.

    .

  •   George Lundberg, MD

    Article from the Miami Herald curated by Contributing Editor George Lundberg, MD, who notes: 

    The RenovoCath chemotherapy device permits targeted delivery of usual chemotherapy drugs directly into, and limited to, localized but inoperable pancreatic cancers. It is currently being tested in a phase 3 clinical trial.

    .

  •   George Lundberg, MD

    PDF from the National Comprehensive Cancer Network curated by Contributing Editor George Lundberg, MD, who notes: 

    The National Comprehensive Cancer Network (NCCN) has issued a 2020 edition of its Guidelines for Patients about Diffuse Large B-Cell Lymphoma.

    .

  •   George Lundberg, MD

    PDF from the National Comprehensive Cancer Network curated by Contributing Editor George Lundberg, MD, who notes: 

    The National Comprehensive Cancer Network (NCCN) has issued a 2020 edition of its Guidelines for Patients about Pediatric Acute Lymphoblastic Leukemia.

    .

  •   George Lundberg, MD

    PDF from the National Comprehensive Cancer Network curated by Contributing Editor George Lundberg, MD, who notes: 

    The National Comprehensive Cancer Network (NCCN) has issued a 2020 edition of its Guidelines for Patients about Kidney Cancer.

    .

  •   George Lundberg, MD

    PDF from the National Comprehensive Cancer Network curated by Contributing Editor George Lundberg, MD, who notes: 

    The National Comprehensive Cancer Network (NCCN) has issued a 2020 edition of its Guidelines for Patients about Liver Cancer.

    .

    Go to full document published by the NCCN.